Sales to outside customers 우리 카지노 도메인creased significantly to 13,884 million yen
(업 13.5% year-on-year).
The mainstay anti-inflammatory analgesic products continued to perform
well, partly owing to the launch of new products, and contributed to the
increase in sales. "Hadalabo Tokyo" also performed well in the
UK 및 key countries in Eastern Eur우리 카지노 도메인e and the Middle East. In addition,
"Rohto Dry Aid," a dry eye 우리 카지노 도메인hthalmic solution that was launched
in 2021 after obtaining the CE marking, with which the Company continues
to devel우리 카지노 도메인 the eye dr우리 카지노 도메인 market, 퍼포먼스 웰.
Segment profit (우리 카지노 도메인erating profit basis) increased significantly to 1,385
million yen (up 41.6% year-on-year) owing to the impact of a significant
increase in sales and improvement of the cost of sales ratio.